An interventional study of Personalized Risk Estimation for Crohn's Disease (PRE-Crohn's) tool and Standard Crohn's Disease Education in Inflammatory Bowel Diseases, Crohn Disease and Crohn Colitis, sponsored by Massachusetts General Hospital. Recruiting at 1 site in United States. Open to participants aged 14 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-30.
Sponsored by Massachusetts General Hospital · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Crohn Disease by Massachusetts General Hospital — 7 open to participants now, 8 under way, none of them phase 3. Crohn Disease · Massachusetts General Hospital.
Among the 14 studies in Crohn Disease by Massachusetts General Hospital, this one is one of 2 that started in 2025, is one of 8 with no phase, and was the 9th registered.
1,995 studies on the registry are indexed under Crohn Disease; 477 are open to participants now.
Browse Crohn Disease studies →7 of the 14 studies in Crohn Disease by Massachusetts General Hospital are open now, in 1 country. Recruiting first, the newest first:
Massachusetts General Hospital · Sites in United States
Ages 18–75 · Healthy volunteers
Massachusetts General Hospital · Sites in United States
Ages 14+ · Healthy volunteers
Massachusetts General Hospital · Sites in United States
Ages 18–99
Massachusetts General Hospital · Sites in United States
Ages 18–75 · Healthy volunteers
Massachusetts General Hospital · Sites in United States
Ages 13–20 · Healthy volunteers
By country, each count listing its studies:
Of the 353 Crohn Disease studies recruiting now, 155 (44%) set no upper age limit and 143 (41%) stop at 75 or younger; 94 take children under 18; 56 take healthy volunteers.
This study: 14 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 80 is above the median of 67 across 1,262 interventional studies indexed under Crohn Disease.
Median enrollment 31 across the 9 interventional studies, 50 across the 5 observational. Of the 4 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Massachusetts General Hospital is the lead sponsor of 2,591 studies on the registry; 445 are open to participants now.
Of its 224 completed or terminated interventional studies of FDA-regulated products, 168 (75%) have results posted.
4 of the studies in Crohn Disease by Massachusetts General Hospital that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04508088Massachusetts General HospitalSkeletal Health and Bone Marrow Composition in Newly Diagnosed Adolescents With Crohn Disease | 2026-12 |
| NCT04565821Massachusetts General HospitalFeasibility Study to Assess a Trans-nasal Intestinal Potential Difference Probe | 2027-04-30 |
| NCT07033208Massachusetts General HospitalFeasibility of a Wireless Thermal Capsule Endoscopy to Detect Gastrointestinal Thermal Variance | 2027-04-30 |
| NCT05332639Massachusetts General HospitalPersonalized Risk Estimation for Crohn's Disease (PRE-Crohn's): Implementation and Feasibility | 2027-11 |
Add all 4 to your calendar (.ics) → With an account.
Among the 14 studies in Crohn Disease by Massachusetts General Hospital, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of this study is to develop and assess the feasibility and effect of a web-based, personalized risk-estimation for Crohn's disease (PRE-Crohn's) tool on behaviors and biomarkers associated with risk for Crohn's disease in unaffected first-degree relatives of patients with inflammatory bowel disease. We hypothesize that personalized risk disclosure via the PRE-Crohn's educational tool is both feasible and successful in modifying behaviors associated with Crohn's disease risk and normalizing pre-clinical disease biomarkers when compared to standard Crohn's disease education. Broadly, completion of this project will also help elucidate the role of lifestyle and dietary factors in pre-clinical Crohn's disease development in high-risk individuals, and provide novel insight into potential strategies for disease prevention in this population.
1,995 studies on the registry are indexed under Crohn Disease; 477 are open to participants now.
This study's planned enrollment of 80 is above the median of 67 across 1,262 interventional studies indexed under Crohn Disease.
Browse Crohn Disease studies →Massachusetts General Hospital is the lead sponsor of 2,591 studies on the registry; 445 are open to participants now.
Of its 224 completed or terminated interventional studies of FDA-regulated products, 168 (75%) have results posted.
Compared within Crohn Disease, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Inflammatory Bowel Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Personalized Risk Estimation for Crohn's Disease (PRE-Crohn's) tool
Behavioral: Personalized Risk Estimation for Crohn's Disease (PRE-Crohn's) tool
Standard Crohn's Disease Education
Behavioral: Standard Crohn's Disease Education
We will develop a web-based, personalized risk estimation for CD (PRE-Crohn's) tool to quantitate participants' relative risk (RR) and lifetime risk of CD based on known risk factors for disease. We will consider the following risk factors for Crohn's disease: body mass index (BMI); smoking history; NSAID use; intake of fruit, fiber, and added sugar; oral contraceptive use (females); antibiotic use; breast-feeding; pets in home; and anti-microbial biomarker positivity. This tool will also display a participants' personalized summary of their risk factors for CD as well as educational tools for modifying these factors. Construction of this tool is based on the Your Disease Risk tool developed by the Siteman Cancer Center at Washington University in St. Louis School of Medicine. The interventional group will also receive standard education about Crohn's disease (comparison group intervention) via the web-based tool.
Also known as: Intervention Arm
The comparison group will receive standard education about Crohn's disease, which will include information regarding the prevalence of disease, clinical presentation including signs and symptoms of disease, and treatment options including available medications. Upon completion of the study, the comparator arm will be given the option of receiving their personalized risk of Crohn's disease with the PRE-Crohn's tool as well.
Also known as: Comparator Arm
Total enrollment (n) at 1.5 years and retention rate (%) at study conclusion
The total enrollment at 1.5 years and the retention rate recorded at the conclusion of the study will be measured based on completion of the 6-month survey.
Time frame: 1.5 years and time of study completion
Motivation to change smoking behavior
We will measure change in contemplation ladder scores for motivation to change smoking behavior (yes/no for achieving a 1-point increase)
Time frame: 8 weeks and 6 months
Motivation to change diet
We will measure change in contemplation ladder scores for motivation to change diet (yes/no for achieving a 1-point increase)
Time frame: 8 weeks and 6 months
Motivation to change physical activity
We will measure change in contemplation ladder scores for motivation to change physical activity (yes/no for achieving a 1-point increase)
Time frame: 8 weeks and 6 months
Change in physical activity
We will measure change in physical activity (MET-hours/week)
Time frame: 8 weeks and 6 months
Change in fruit intake
We will measure change in fruit intake (servings/day)
Time frame: 8 weeks and 6 months
Change in vegetable intake
We will measure change in vegetable intake (servings/day)
Time frame: 8 weeks and 6 months
Change in processed meat intake
We will measure change in processed meat intake (servings/day)
Time frame: 8 weeks and 6 months
Change in fiber intake
We will measure change in fiber intake (grams/day)
Time frame: 8 weeks and 6 months
Change in added sugar intake
We will measure change in added sugar intake (grams/day)
Time frame: 8 weeks and 6 months
Change in smoking behaviors
We will measure change in smoking behaviors including current smoking vs non-smoking and cigarettes/day
Time frame: 8 weeks and 6 months
Change in C-reactive protein (CRP; mg/L)
We will measure change in CRP (mg/L)
Time frame: 8 weeks and 6 months
Change in fecal calprotectin (mcg/g)
We will measure change in fecal calprotectin (mcg/g)
Time frame: 8 weeks and 6 months
Change in seropositivity for antimicrobial biomarkers
We will measure several Crohn's disease associated antimicrobial biomarkers including ASCA IgA and IgG, anti-OmpC, anti-CBir1, anti-A4-Fla2 and anti-FlaX will be assayed using the PROMETHEUS® IBD sgi Diagnostic® panel. Positivity for each of these components are defined as follows: ASCA IgA \> 9.2 EU/mL; ASCA IgG \> 11.9 EU/mL; anti-OmpC \> 11.3 EU/mL; anti-CBir1 \> 35.4 EU/mL; anti-A4-Fla2 \> 32.4 EU/mL and anti-FlaX \> 36.0 EU/mL. Total biomarker positivity (secondary outcome) will be defined as the presence of 1 or more positive individual biomarkers above. We will then assess for change in total biomarker positivity at 8 weeks and 6 months compared to baseline.
Time frame: 8 weeks and 6 months
Plan to share: Yes — Aggregate-level results of from this study will be reported on clinicaltrials.gov. De-identified individual-level data will be uploaded to a separate controlled access repository and can be available upon reasonable request and per controlled access repository standard terms and procedures.
Time frame: All scientific data generated from this project will be made available as soon as possible, and no later than the time of publication or the end of the funding period, whichever comes first. The duration of preservation and sharing of the data will be a minimum of 10 years after the funding period.
Access criteria: A controlled repository will be used to store and protect individual patient data. To access data arising from this project, users must complete a data request form and Data Use Agreement (DUA), which limits subsequent use to the terms of the approved request and requires that users maintain data security, and refrain from any attempts to re-identify research participants or engage in any unauthorized uses of the data. To get access to the data, the user must submit a valid scientific question, include a statistical analysis plan.
Started Oct 2025 (actual). Primary completion is estimated for Nov 2027, 25 months after the start.
Of 290 non-industry interventional studies with no phase under Crohn Disease, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 67. This study's planned 25 months is below that.
Counting every sponsor, half of 302 studies reached it within 45 months; a quarter within 21 and three quarters within 65.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Massachusetts General Hospital →